Supply Chain Map
HALOCIK 1159036

HALOZYME THERAPEUTICS, INC.

EDGAR filings
Customers
3
0 disclosed
Suppliers
1
1 disclosed
Top supplier share
33%
of Avid Bioservices, Inc. revenue · FY to 2024-04-30
Top supplier by $
$46.2M
Avid Bioservices, Inc. · FY to 2024-04-30
Latest period
Apr 30, 2024
10-K filed 2024-07-02
SuppliersCustomersAvid Bioservices, Inc.33% · $46.2MAvid Bioservices, Inc. · 33% of their revenue · $46.2M · FY to 2024-04-30 · 10-K filed 2024-07-02No customers disclosedHALO
Band height is the estimated dollar value: the disclosed share × the discloser's revenue for that period (latest full year where available) or federal dollars obligated. Each side is scaled on its own; dashed outlines are named without a figure. Click a band to open its source.

Customers 3

Companies HALO discloses as major customers, as a share of HALO revenue. 0 active, 3 lapsed.

Company% of HALO revenueEst. revenuePeriodTrendStatusSource
ARGX
ARGENX SE
 23%$45.1M FY 2019-12-31
FY ending 2019-12-31: 23%
Lapsed
Last seen 2019-12-31
 10-K 2020-02-24
argenx 23 % — % — %
10-K filed 2020-02-24 Period FY 2019-01-01 to 2019-12-31 (23%)Accession 0001159036-20-000013
ABBV
AbbVie Inc.
 4%$5.9M FY 2016-12-31
FY ending 2015-12-31: 17%FY ending 2016-12-31: 4%−13.0pp
Lapsed
Last seen 2016-12-31
 10-K 2018-02-20
AbbVie — 4 % 17 %
10-K filed 2018-02-20 Period FY 2016-01-01 to 2016-12-31 (4%), FY 2015-01-01 to 2015-12-31 (17%)Accession 0001159036-18-000011
PFE
PFIZER INC
 1%$753.3K FY 2014-12-31
FY ending 2012-12-31: 22%FY ending 2013-12-31: 4%FY ending 2014-12-31: 1%−3.0pp
Lapsed
Last seen 2014-12-31
 10-K 2015-03-02
Pfizer 1 % 4 % 22 %
10-K filed 2015-03-02 Period FY 2014-01-01 to 2014-12-31 (1%), FY 2013-01-01 to 2013-12-31 (4%), FY 2012-01-01 to 2012-12-31 (22%)Accession 0001159036-15-000041

Suppliers 1

Companies that disclose HALO as a major customer, as a share of their own revenue. 1 active, 0 lapsed.

Company% of their revenueEst. $ from HALOPeriodTrendStatusSource
Avid Bioservices, Inc.
Avid Bioservices, Inc.
 33%$46.2M FY 2024-04-30
FY ending 2020-04-30: 28%FY ending 2021-04-30: 51%FY ending 2022-04-30: 41%FY ending 2023-04-30: 53%FY ending 2024-04-30: 33%−20.0pp
Active 10-K 2024-07-02
Halozyme Therapeutics, Inc. (1) U.S. 33 % 53 % 41 %
10-K filed 2024-07-02 Period FY 2023-05-01 to 2024-04-30 (33%), FY 2022-05-01 to 2023-04-30 (53%), FY 2021-05-01 to 2022-04-30 (41%)Accession 0001683168-24-004610
Halozyme Therapeutics, Inc. (1) U.S. 53 % 41 % 51 %
10-K/A filed 2024-04-24 Period FY 2020-05-01 to 2021-04-30 (51%)Accession 0001683168-24-002656
Halozyme Therapeutics, Inc. (1) U.S. 41 % 51 % 28 %
10-K filed 2022-06-29 Period FY 2019-05-01 to 2020-04-30 (28%)Accession 0001683168-22-004704

Unnamed major customers

Disclosed without names in the fiscal year ending 2025-12-31. Identities are not inferred.

  • Partner A41%
  • Partner B17%
  • Partner C16%
  • Partner D6%

Alerts are coming

Get an email when HALO's disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.

We store only your email, the page you signed up from and the time. Privacy